ORMP - Oravax Medical gets clearance for Phase 1 oral COVID-19 vaccine trial in South Africa

Oramed Pharmaceuticals (NASDAQ:ORMP) company Oravax Medical has received clearance from the South African Health Products Regulatory Authority to commence patient enrollment in the company's early-stage oral COVID-19 vaccine trial. "An oral COVID-19 vaccine would eliminate several barriers to rapid, widescale distribution, potentially enabling people to administer the vaccine themselves at home," CEO Nadav Kidron said. "Following this Phase 1 trial, our intention is to move forward with a Phase 2/3 trial for emergency use approval in relevant countries," he added.

For further details see:

Oravax Medical gets clearance for Phase 1 oral COVID-19 vaccine trial in South Africa